Letermovir

  • CAT Number: I005468
  • CAS Number: 917389-32-3
  • Molecular Formula: C29H28F4N4O4
  • Molecular Weight: 572.6
  • Purity: 98%
Inquiry Now

Letermovir is a small molecule inhibitor of human cytomegalovirus viral replication (EC50 = ~5 nM with a selectivity index >15,000) that targets viral DNA cleavage and packaging. Letermovir functions to prevent viral DNA concatemers from forming the proper unit length and interferes with virion maturation.


Catalog Number I005468
CAS Number 917389-32-3
Synonyms

2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid

Molecular Formula C29H28F4N4O4
Purity 98%
Target CMV
Solubility 10 mM in DMSO
Appearance Solid Powder
Storage Store at -20°C
Analysis method HPLC
IC50 5.1±1.2 nM (EC50, HCMV-AD169 strain, CPE reduction assay)
InChIKey FWYSMLBETOMXAG-QHCPKHFHSA-N
Reference

1: Erb-Zohar K, Kropeit D, Scheuenpflug J, Stobernack HP, Hulskotte E, van Schanke A, Zimmermann H, R&uuml;bsamen-Schaeff H. Intravenous Hydroxypropyl &beta;-Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single-Ascending, and Multiple-Dose Trial. Clin Transl Sci. 2017 Nov;10(6):487-495. doi: 10.1111/cts.12483. Epub 2017 Jul 4. PubMed PMID: 28675594.<br />
2: Bowman LJ, Melaragno JI, Brennan DC. Letermovir for the management of cytomegalovirus infection. Expert Opin Investig Drugs. 2017 Feb;26(2):235-241. doi: 10.1080/13543784.2017.1274733. Epub 2016 Dec 28. Review. PubMed PMID: 27998189.<br />
3: Wildum S, Zimmermann H, Lischka P. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015;59(6):3140-8. doi: 10.1128/AAC.00114-15. Epub 2015 Mar 16. PubMed PMID: 25779572; PubMed Central PMCID: PMC4432118.<br />
4: Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610-3. doi: 10.1128/AAC.01794-13. Epub 2013 Nov 4. PubMed PMID: 24189264; PubMed Central PMCID: PMC3910730.<br />
5: Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93. doi: 10.1128/JVI.05265-11. Epub 2011 Jul 13. PubMed PMID: 21752907; PubMed Central PMCID: PMC3187482.

Request a Quote